This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Icon PLC (ICLR) Down 8.9% Since Last Earnings Report?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GEHC Stock Gains Following Cardiology Solutions Portfolio Expansion
by Zacks Equity Research
GE HealthCare aims to enhance efficiency and precision care for multiple types of cardiac procedures through the introduction of improved interventional solutions.
Here is Why Growth Investors Should Buy Cencora (COR) Now
by Zacks Equity Research
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year.
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
by Vasundhara Sawalka
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NVDA, COR, JBL and KLAC hold promise.
Beat the Market the Zacks Way: Amgen, DRDGOLD, Anavex in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
CVS Health (CVS) Down 0.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Cencora (COR) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Avoid Betting on Danaher Stock Right Now
by Zacks Equity Research
Persistent softness in the Life Sciences segment weighs on DHR's performance. An increase in operating expenses is an added concern.
Here's Why Cencora (COR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Indrajit Bandyopadhyay
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Why Is Cencora (COR) Up 3.1% Since Last Earnings Report?
by Zacks Equity Research
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Stock Reports for NVIDIA, Tesla & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Tesla, Inc. (TSLA) and American Express Company (AXP), as well as two micro-cap stocks CSP Inc. (CSPI) and NetSol Technologies, Inc. (NTWK).
Brookdale Expands Real Estate Portfolio With Strategic Acquisitions
by Zacks Equity Research
BKD expands its real estate footprint with the closure of two acquisitions.
Zacks.com featured highlights include Sprouts Farmers Market, Cencora and American Express
by Zacks Equity Research
Sprouts Farmers Market, Cencora and American Express have been highlighted in this Screen of The Week article.
Scoop Up These 3 GARP Stocks to Receive Handsome Returns
by Vasundhara Sawalka
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, COR and AXP are some stocks that hold promise.
3 Reasons Why Growth Investors Shouldn't Overlook Cencora (COR)
by Zacks Equity Research
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Has Concentra Group Holdings Parent, Inc. (CON) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Concentra Group (CON) and Cencora (COR) have performed compared to their sector so far this year.
Danaher Rewards Shareholders With 18.5% Dividend Increase
by Zacks Equity Research
DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Cencora (COR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks.com featured highlights include American Express, Cencora and Tempur Sealy International
by Zacks Equity Research
American Express, Cencora and Tempur Sealy International have been highlighted in this Screen of The Week article.
3 GARP Stocks That Investors Can Scoop Up for Maximum Returns
by Vasundhara Sawalka
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. AXP, COR and TPX hold promise.
Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings?
by Indrajit Bandyopadhyay
McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Can MCK overcome its sustaining challenges with robust finances and innovation?